Abstract
Sesh K. Sunkara, Christos Venetis, Thomas D’Hooghe, Tamara Hunter, Susana Montenegro, Frank Broekmans
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Pregnancy at age 35 years or older: ACOG Obstetric Care Consensus No. 11
10.1097/aog.0000000000004873 · 2022
Exploring the complex landscape of delayed childbearing: factors, history, and long-term implications
10.7759/cureus.46291 · 2023
Age at first birth, mode of conception and psychological wellbeing in pregnancy: findings from the parental age and transition to parenthood Australia (PATPA) study
10.1093/humrep/der076 · 2011
Time as an outcome measure in fertility-related clinical studies: long-awaited
10.1093/humrep/deaa138 · 2020
The updated understanding of advanced maternal age
10.1016/j.fmre.2023.09.013 · 2024
The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening
10.1016/j.fertnstert.2013.11.004 · 2014
Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity
10.1016/j.fertnstert.2020.10.051 · 2021
Reproduction at an advanced maternal age and maternal health
10.1016/j.fertnstert.2015.03.004 · 2015
Delayed child-bearing
10.1016/s1701-2163(16)35138-6 · 2012
Unresolved referenced work
Kept as external metadata until matched
ART in Europe 2019: results generated from European registries by ESHRE†
10.1093/humrep/dead197 · 2023
Female ageing and reproductive outcome in assisted reproduction cycles
10.11622/smedj.2014081 · 2014
Projecting the contribution of assisted reproductive technology to completed cohort fertility
10.1007/s11113-023-09765-3 · 2023
Childbirth timing and completed family size by the mode of conception-the role of medically assisted reproduction: a population-based cohort study in Australia
10.1016/j.lanwpc.2023.100686 · 2023
Evolution of cumulative live birth and dropout rates over six complete IVF/ICSI cycles: a large prospective cohort study
10.1016/j.rbmo.2021.01.005 · 2021
What do healthy women know about the consequences of delayed childbearing
10.1080/10810730.2013.825677 · 2013
Age and fertility: a study on patient awareness
10.5935/1518-0557.20160024 · 2016
Awareness, knowledge, and perceptions of infertility, fertility assessment, and assisted reproductive technologies in the era of oocyte freezing among female and male university students
10.1007/s10815-016-0717-1 · 2016
Knowledge of age-related fertility decline in women: a systematic review
10.1016/j.ejogrb.2018.09.030 · 2018
Guidelines informing counseling on female age-related fertility decline: a systematic review
10.1007/s10815-020-01967-4 · 2021
ESHRE guideline: female fertility preservation†
10.1093/hropen/hoaa052 · 2020
Assisted reproduction with advancing paternal and maternal age: an Ethics Committee opinion
10.1016/j.fertnstert.2025.03.031 · 2025
Achieving two live births from one ovarian stimulation cycle: the one-and-done approach revisited
10.1016/j.fertnstert.2025.07.029 · 2026
Is there an association between oocyte number and embryo quality? A systematic review and meta-analysis
10.1016/j.rbmo.2019.06.013 · 2019
Is more better? A higher oocyte yield is independently associated with more day-3 euploid embryos after ICSI
10.1093/humrep/dey342 · 2019
Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles
10.1093/humrep/der106 · 2011
Cumulative live birth rates for women returning to ART treatment for a second ART-conceived child
10.1093/humrep/deaa030 · 2020
A novel predictive model to estimate the number of mature oocytes required for obtaining at least one euploid blastocyst for transfer in couples undergoing in vitro fertilization/intracytoplasmic sperm injection: the ART Calculator
10.3389/fendo.2019.00099 · 2019
Validation of ART Calculator for Predicting the Number of Metaphase II Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection
10.3389/fendo.2019.00917 · 2019
The number of autologous, vitrified mature oocytes needed to obtain three euploid blastocysts increases with age
10.1016/j.fertnstert.2025.04.023 · 2025
Unresolved referenced work
Kept as external metadata until matched
Fertility and the aging male
2011
The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development
10.1093/humrep/17.4.990 · 2002
Male age negatively impacts embryo development and reproductive outcome in donor oocyte assisted reproductive technology cycles
10.1016/j.fertnstert.2007.06.009 · 2008
The effect of paternal age on outcome in assisted reproductive technology using the ovum donation model
10.1177/1933719113506497 · 2014
High aneuploidy rates observed in embryos derived from donated oocytes are related to male aging and high percentages of sperm DNA fragmentation
10.4137/cmrh.s32769 · 2015
Unresolved referenced work
2021
Age-associated changes in cumulus cells and follicular fluid: the local oocyte microenvironment as a determinant of gamete quality
10.1093/biolre/ioab241 · doi-reference
Aging conundrum: a perspective for ovarian aging
10.3389/fendo.2022.952471 · doi-reference
Too many embryos: a critical perspective on a global challenge
10.1007/s10815-024-03159-w · doi-reference
Recombinant human follicle-stimulating hormone alfa dose adjustment in US clinical practice: an observational, retrospective analysis of a real-world electronic medical records database
10.3389/fendo.2021.742089 · doi-reference
Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years, (2007-2017)
10.1186/s12958-021-00744-x · doi-reference
Decision points for individualized hormonal stimulation with recombinant gonadotropins for treatment of women with infertility
10.1080/09513590.2019.1650345 · doi-reference
Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the follicle-to-oocyte (FOI) index
10.3389/fendo.2018.00589 · doi-reference
How to personalize ovarian stimulation in clinical practice
10.4274/jtgga.2017.0058 · doi-reference
Biomarkers of ovarian response: current and future applications
10.1016/j.fertnstert.2012.11.051 · doi-reference
Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis
10.1093/humupd/dmae032 · doi-reference
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI)
10.1002/14651858.cd012693.pub3 · doi-reference
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI)
10.1002/14651858.cd012693.pub2 · doi-reference
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria
10.1093/humrep/der092 · doi-reference
Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials
10.1186/s12958-021-00759-4 · doi-reference
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years
10.1016/j.rbmo.2023.103725 · doi-reference
Reply: biosimilars versus the originator of follitropin alfa in ART: eyes wide shut
10.1093/humrep/deaf145 · doi-reference
Methodological concerns and clinical relevance: a critical appraisal of the meta-analysis on biosimilars versus originator follitropin alfa in ART
10.1093/humrep/deaf144 · doi-reference
Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis
10.1093/humrep/deae274 · doi-reference
Follitropin alfa biosimilars: unfounded doubts on the road to reproductive care
10.1093/humrep/deaf143 · doi-reference
Follicle-stimulating hormone biological products: does potency predict clinical efficacy
10.3390/ijms24109020 · doi-reference
Recombinant follicle-stimulating hormone (rFSH) versus other recombinant or urinary gonadotropins for ovarian stimulation in assisted reproductive technology cycles
10.1002/14651858.cd005354.pub3 · doi-reference
Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection
10.1016/j.fertnstert.2020.03.029 · doi-reference
Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial
10.3109/09513590.2011.650742 · doi-reference
A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer
10.1016/j.fertnstert.2011.12.016 · doi-reference
Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients
10.1016/j.fertnstert.2007.05.039 · doi-reference
Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study
10.1093/humrep/den220 · doi-reference
Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial
10.1093/humrep/del284 · doi-reference
PGT-A: what's it for, what's wrong
10.1007/s10815-025-03400-0 · doi-reference
The cost of a euploid embryo identified from preimplantation genetic testing for aneuploidy (PGT-A): a counseling tool
10.1007/s10815-018-1275-5 · doi-reference
The use of preimplantation genetic testing for aneuploidy: a committee opinion
10.1016/j.fertnstert.2024.04.013 · doi-reference
Good practice recommendations on add-ons in reproductive medicine†
10.1093/humrep/dead184 · doi-reference
Clinical management of mosaic results from preimplantation genetic testing for aneuploidy of blastocysts: a committee opinion
10.1016/j.fertnstert.2023.08.969 · doi-reference
PGDIS position statement on the transfer of mosaic embryos 2021
10.1016/j.rbmo.2022.03.013 · doi-reference
PGT-A is associated with a reduced live birth rate in routine practice: evidence from the UK ART register
10.1016/j.rbmo.2026.105747 · doi-reference
Safety and effectiveness of ten common in-vitro fertilisation add-ons: a systematic review and meta-analysis
10.1016/s3050-5038(26)00054-3 · doi-reference
DuoStim - a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes. A systematic review
10.1080/03009734.2020.1734694 · doi-reference
The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles
10.1093/humrep/dez100 · doi-reference
Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women ≥38 years old
10.1093/humrep/dey295 · doi-reference
Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos
10.1093/humrep/dev316 · doi-reference
The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China
10.1093/humrep/det303 · doi-reference